ZOLL Medical Corporation on Tuesday announced a definitive agreement to acquire Cardiac Science Corporation (CSC), a portfolio company of Aurora Resurgence, a Los Angeles-based private equity investment firm, for an undisclosed value.
With executive offices in Deerfield, Wisconsin, Cardiac Science Corporation (CSC) is leading provider of automated external defibrillators (AEDs), related services and accessories.
The company said sudden cardiac arrest (SCA), an abrupt disruption of the heart's function, which causes a lack of blood flow to vital organs, claims more than 350,000 lives each year in the US. If a victim does not receive CPR and early defibrillation from an AED, chances of survival decrease 10% with each passing minute.
ZOLL's lifesaving AED management programme technology reportedly enables dispatchers to communicate the locations of registered AEDs to callers reporting potential sudden cardiac arrest incidents.
Hence, Cardiac Science's addition to ZOLL's AED Link programme will allow more 9-1-1 agencies to help put AEDs in the hands of laypersons and first responders to support life-saving action.
ZOLL Medical develops and markets medical devices and software solutions to advance emergency care and save lives and part of Asahi Kasei Group company.
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
GEN and Sulfateq report positive Phase 1 data for SUL-238 in Alzheimer's
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement